LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
PLRX
Pliant Therapeutics, Inc.
There isn't enough reported data to score PLRX yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
PLRX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Strong |
PLRX's balance sheet is currently strong, but its revenue and profitability are weak. There isn't enough data to rate its cash flow.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
PLRX PE Valuation
PLRX has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
PLRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect PLRX's revenue to grow, with its earnings and profitability holding steady.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over PLRX on earnings quality, reporting a profit while its opponent remains loss making.
PLRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.44 | +$1.44 |
| Q2 2026 | -$1.48 | +$1.92 |
| Q1 2026 | -$1.83 | +$1.78 |
| Q4 2025 | -$2.43 | +$1.04 |
| Q3 2025 | -$2.88 | +$0.45 |
| Q2 2025 | -$3.40 | -$0.32 |
| Q1 2025 | -$3.61 | -$0.75 |
| Q4 2024 | -$3.47 | -$0.72 |
PLRX is still losing money, but far less than before: $1.44 per share over the past year, against $3.61 at its worst in early 2025.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
PLRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2023 | $248K | -95% |
| Q1 2023 | $1.3M | +6.6% |
| Q4 2022 | $2M | -1.7% |
| Q3 2022 | $1.5M | -8% |
| Q2 2022 | $5M | +179% |
| Q1 2022 | $1.2M | -43% |
| Q4 2021 | $2M | -55% |
| Q3 2021 | $1.6M | -67% |
PLRX's revenue has slid since its 2019 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2023 | -19084% | -18490 points |
| Q1 2023 | -3160% | -902 points |
| Q4 2022 | -1903% | -673 points |
| Q3 2022 | -2156% | -472 points |
| Q2 2022 | -594% | +686 points |
| Q1 2022 | -2259% | -1205 points |
| Q4 2021 | -1231% | -805 points |
| Q3 2021 | -1684% | -1338 points |
PLRX's operating margin was −19084% last quarter, down 18490 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over PLRX on cash generation, producing positive trailing cash flow while its opponent burns cash.
PLRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$17M | +$4.1M |
| Q2 2026 | -$12.8M | +$27.9M |
| Q1 2026 | -$19.2M | +$29.9M |
| Q4 2025 | -$17.8M | +$30.1M |
| Q3 2025 | -$21.1M | +$12.1M |
| Q2 2025 | -$40.7M | +$5.8M |
| Q1 2025 | -$49.1M | -$17.4M |
| Q4 2024 | -$47.9M | -$22.7M |
PLRX has burned cash in almost every quarter: −$67M over the past year, against −$159M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over PLRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
PLRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +24.7K shares |
| 1 year | +0.9% | +537K shares |
| 3 years | +3.8% | +2.3M shares |
| 5 years | +73% | +26.2M shares |
| Available history | +184% | +40.1M shares |
PLRX has 62M diluted shares, up 0.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2020 | — |
| Q4 2019 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
PLRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2020 | -2.7x | Net Cash |
| Q2 2020 | -7.4x | Net Cash |
| Q1 2020 | -4.5x | Net Cash |
PLRX has more cash than debt.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
PLRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 25.9 | Oversold |
| Stochastic | 4.0 | Oversold |
PLRX's weekly RSI is 26 (oversold) and its Stochastic is 4 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
PLRX PE vs Healthcare Sector
| Metric | PLRX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
PLRX has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over PLRX on trend strength, trading above more of its moving averages.
PLRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.91 | 19% below |
| 20 week MA | $1.04 | 29% below |
| 50 week MA | $1.15 | 36% below |
| 100 week MA | $2.19 | 66% below |
| 200 week MA | $9.83 | 92% below |
PLRX is in a downtrend: it's below all five of its weekly moving averages, and 92% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over PLRX on returns for 2026, with the stronger performance.
PLRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $22.3 | $25.4 | +14% |
| 2021 | $25.4 | $15.4 | -40% |
| 2022 | $15.4 | $18.2 | +19% |
| 2023 | $18.2 | $18.1 | -0.5% |
| 2024 | $18.1 | $13.6 | -25% |
| 2025 | $13.6 | $1.21 | -91% |
| 2026 YTD | $1.21 | $0.74 | -39% |
PLRX has finished three years in a row lower, and it's down 39% so far in 2026.